Loading...
XSTO
ORX
Market cap92mUSD
Dec 05, Last price  
25.00SEK
1D
1.21%
1Q
7.07%
Jan 2017
-33.51%
IPO
-72.21%
Name

Orexo AB

Chart & Performance

D1W1MN
XSTO:ORX chart
P/E
—
P/S
1.46
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.50%
Rev. gr., 5y
-6.93%
Revenues
590m
-7.64%
62,352,000131,956,0000233,346,000236,104,000210,499,000199,614,000326,278,000429,355,000570,316,000643,338,000705,800,000643,700,000783,100,000844,800,000663,600,000565,000,000624,300,000638,800,000590,000,000
Net income
-203m
L+58.22%
-43,249,000-32,943,0000-103,054,000-98,079,000-89,246,000-392,009,000-85,863,000-154,936,000-56,584,000-197,987,00029,000,00023,200,000137,900,000219,100,000-84,400,000-223,500,000-177,600,000-128,300,000-203,000,000
CFO
-33m
L-65.68%
-45,382,000-25,279,000-160,485,000-101,490,000-133,927,000-42,967,000-117,228,00028,668,000-263,201,000-487,300,000-102,193,000156,200,000146,600,000242,000,000287,000,00016,800,000-229,000,000-156,600,000-95,000,000-32,600,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
URL
https://orexo.se/
IPO date
Nov 09, 2005
Employees
120
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT